Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Nautilus Biotechnology is raising $200,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sujal Patel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nautilus Biotechnology
Born from the founders recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

To learn more about Nautilus Biotechnology, visit http://www.nautilus.bio/

Contact:
Sujal Patel, Chief Executive Officer
206-333-2001
sujalp@nautilus.bio
https://www.linkedin.com/in/patelsujal/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved